Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Influenza Vaccine in Chinese Infants Aged 6-35 Months
NCT06049927Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quadrivalent influenza vaccine in influenza (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rates of HI antibody, Geometric Mean Titers (GMTs) of HI antibody and 1 more. Started Sep 2023; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06049927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049927.